UT Health San Antonio wins ‘Best Company Perks & Benefits’ award from Comparably

October 20, 2023

UT Health San Antonio has earned a “Best Company Perks & Benefits” award from Comparably, a website that compiles job listings and company culture information, based on feedback from surveys of its current employees. This marks the third award UT Health San Antonio has received from Comparably, after receiving “Best Company for Diversity” (December 2022) […]




UT Health San Antonio awarded Best Company Perks & Benefits

October 19, 2023

  UT Health San Antonio was awarded Best Company Perks & Benefits by Comparably, an employer recruitment, culture and branding site. The university received this award out of tens of thousands of large companies based on real-time feedback from current employees over the past 12 months. This award measures how satisfied employees are with their benefits, programs […]




UT Health San Antonio honored for digital excellence by the College of Healthcare Information Management Executives

October 19, 2023

UT Health San Antonio has been recognized as a “Digital Health Most Wired” organization by the College of Healthcare Information Management Executives (CHIME), an organization serving senior health care information technology leaders. The award is based on an annual survey designed to identify and recognize health care organizations that exemplify best practices through their adoption, […]




UT Health San Antonio opens spine center

October 13, 2023

The Spine Center at UT Health San Antonio is now open, offering complete spine care for adults and children from a team of neurosurgeons, orthopaedic surgeons and specialists in non-operative care for all spine issues.





UT Health San Antonio becomes first civilian center in South Texas to launch FDA-approved radiotherapy treatment for advanced prostate cancer

October 6, 2023

  The University of Texas Health Science Center at San Antonio (UT Health San Antonio) announces the successful launch of Pluvicto, a radiopharmaceutical used to treat patients with advanced metastatic prostate cancer. Approved by the U.S. Food and Drug Administration in March of 2022, Pluvicto is a novel targeted molecular therapy that delivers radiation treatment […]